Childhood cerebral adrenoleukodystrophy (CCALD) can present as a first-time seizure early enough in the disease course to allow for disease-modifying therapy. Seizure severity correlates with disease burden on MRI (Loes ≥6) and more advanced clinical symptoms. The prevalence of seizures in CCALD appears higher than previously recognized, indicating that X-linked adrenoleukodystrophy should be in the differential diagnosis for males presenting with first-time seizure.
Why does infantile epileptic spasms syndrome (IESS) occur with a variety of underlying conditions and why does it respond to adrenocorticotrophin hormone (ACTH)/corticosteroids? Our scoping review summarizes five hypotheses from the literature: gene/epigenetic regulation, stress/HPA axis activation, neuroinflammation/immune function, altered neuronal transmission, and metabolic dysfunction. Evidence for ACTH/corticosteroids altering these processes is limited. IESS likely involves interacting processes affecting neurodevelopment. Understanding aetiopathogenic mechanisms further may lead to improved therapies and outcomes.
Non-epileptic seizures are invariably situation-related seizures.
Non-epileptic seizures were classified as altered consciousness, movement disorders, dysaesthesia, and vomiting.
Non-epileptic seizures were characterized by the absence of complete consciousness loss and were accompanied by rapid recovery.
Non-epileptic seizures can occur simultaneously or consecutively with another.
Supplementary food can be effective in preventing the development of sustained exercise-induced movement disorders.
Glucose transporter type 1 deficiency syndrome-associated non-epileptic seizures (NESz) are situation-related with specific provoking and ameliorating factors. Ongoing epileptic seizures (ESz) require prompt treatment with antiseizure medications (ASM), while ongoing NESz require rest and energy supplementation, although oral supplementation or rest without ASM would be risky in ESz. Differentiating NESz from ESz is essential for treatment selection, especially during acute exacerbation.
This original article is commented by Korff on pages 1403–1404 of this issue.
The experience with neurostimulation for childhood epilepsy is far less extensive than for adults. Nevertheless, the implementation of these techniques could be of great value, especially considering the detrimental effects of ongoing seizures on the developing brain. In this review, we discuss the available evidence for neurostimulation for childhood epilepsy.
In two successive cohorts of patients with Dravet syndrome (CRéER-1 1991–2004, CRéER-2 2005–2021) who initiated stiripentol before 2 years of age, the percentage of responders with a 50%, 75%, 100% (seizure free [SF]) decrease in both 5–30 minute- and >30 minute-duration tonic–clonic seizures (TCS) continued to increase between short-term and long-term treatment (light and dark columns respectively). Stiripentol also decreased the frequency of emergency hospitalizations.
This original article is commented on by Vasquez and Wirrell on pages 1545–1546 of this issue.
Please check your email for instructions on resetting your password.
If you do not receive an email within 10 minutes, your email address may not be registered,
and you may need to create a new Wiley Online Library account.
Request Username
Can't sign in? Forgot your username?
Enter your email address below and we will send you your username
If the address matches an existing account you will receive an email with instructions to retrieve your username